Big Pharma says AI is cutting drug discovery timelines as Anthropic expands in pharma
Large drugmakers are using artificial intelligence deeper in research pipelines, and some say the technology is already shortening the time needed to design new molecules and advance them toward clinical testing. The shift comes as Anthropic pushes further into drug discovery through its own lab, partnerships and software, raising questions over whether AI groups will become suppliers, collaborators or direct rivals to pharmaceutical companies.
Highlights
- Sanofi reports saving at least a year developing asthma drug lunsekimig using AI, including skipping a dose-selection study.
- Novartis and Novo Nordisk state AI reduced drug design cycles from eight to three and cycle duration from eight weeks to four.
- Pharma executives project AI will cut early-discovery timelines by 20–25% in two years and up to 50% within five years.
Drugmakers report faster early-stage development
As reported by Reuters, companies including GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi say they have moved beyond using AI for administrative work such as regulatory filings and are now applying it to molecule design, candidate selection and safety-risk identification.AstraZeneca executive Sharon Barr says the company uses AI across the discovery-to-development pipeline. Sanofi says it saved at least a year in developing asthma treatment lunsekimig by using an AI-enabled approach that helped it skip a dose-selection study, while Novartis says AI tools helped it identify five targets it prioritized for kidney disease treatments.
Bristol Myers says one of its sickle cell anemia candidates would not have been developed without the company's AI systems. Novo Nordisk says AI has reduced the number of design, manufacturing and testing cycles for new molecules from about eight to three, while cutting the duration of each cycle from eight weeks to four.
Novartis President of Biomedical Research Fiona Marshall says the average time from project start to a drug candidate has fallen from three years to about 18 months to two years. Sanofi's Matt Truppo says AI could cut early-discovery timelines by 20% to 25% within two years, and potentially by half within five years, across more than 100 drug development programs.
Earlier, we discussed Pragmatik Labs funding as investor appetite for emerging AI developers remained strong.